fda semaglutide news 🎉Exciting that is now approved for MASH (aka fatty liver disease) “At week 72, the primary efficacy endpoint was based on histology (liver biopsy results). Interim results showed 63% FDA approves obesity drug that

This amplifies and propagates the senescent phenotype and its associated inflammation throughout the tissue [57]

It changed my life for the better

The label expansion is based on a Phase II trial that evaluated Brineura in children aged 16 over three years, with eight patients being less than 3 years old

At the same time, manufacturers are expanding production capabilities and strengthening supply chains to meet the anticipated increase in global demand

Salivary cortisol in long COVID: a marker of broader stress system and circadian rhythm dysregulation

Food texture, temperature, and composition can significantly influence tolerance